Cargando…
Interleukin 6: A biomarker for COVID-19 progression
COVID-19 was discovered in China for the first time in December 2019 and was declared a pandemic by the World Health Organization on March 11, 2020. Due to its rapid geographic expansion over the last three years, it has now become a global health issue. The infection is caused by SARS-CoV-2, which...
Autores principales: | Sebbar, El-houcine, Choukri, Mohammed |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Elsevier Ltd.
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9343743/ https://www.ncbi.nlm.nih.gov/pubmed/35937954 http://dx.doi.org/10.1016/j.matpr.2022.07.387 |
Ejemplares similares
-
Cardiovascular markers and COVID-19
por: Sebbar, El-houcine, et al.
Publicado: (2023) -
Biomarkers Predicting Poor Prognosis in Covid-19 Patients: A Survival Analysis
por: Idrissi, Amjad, et al.
Publicado: (2023) -
Interleukin-6 as a potential biomarker of COVID-19 progression
por: Ulhaq, Zulvikar Syambani, et al.
Publicado: (2020) -
Comparative analysis of clinical and biological characteristics of COVID-19 patients: A retrospective cohort study
por: Yahyaoui, Abir, et al.
Publicado: (2023) -
Interleukin-6 as prognosticator in patients with COVID-19
por: Grifoni, Elisa, et al.
Publicado: (2020)